1461083889-1065daf3-b64e-49a9-a2aa-c8b8023b9e50

1. A semiconductor device, comprising:
a semiconductor chip;
a lead that is arranged in a periphery of the semiconductor chip and has a main surface and a rear surface opposed to the main surface;
a wire that is connected to the main surface of the lead and electrically connects the semiconductor chip and the lead; and
a sealing body in which the semiconductor chip, the lead and the wire are covered with sealing resin,
wherein the lead has, in an extending direction of the lead, one end located inside the sealing body, the other end located outside the sealing body and a wire connection part to which the wire is connected, and the lead has a first groove in the main surface between the one end and the wire connection part.
2. The semiconductor device according to claim 1,
wherein a linear expansion coefficient of the lead is larger than a linear expansion coefficient of the sealing resin.
3. The semiconductor device according to claim 2,
wherein the lead is made of copper, and the sealing resin is made of epoxy resin containing filler made of silica.
4. The semiconductor device according to claim 1,
wherein the first groove extends in a direction orthogonal to the extending direction of the lead.
5. The semiconductor device according to claim 4,
wherein the first groove is arranged between the wire connection part and the one end of the lead in the extending direction of the lead.
6. The semiconductor device according to claim 4,
wherein the lead has an inner part inside the sealing body and an outer part outside the sealing body, and a width of the outer part in the direction orthogonal to the extending direction of the lead is smaller than a length of the first groove in the direction orthogonal to the extending direction of the lead.
7. The semiconductor device according to claim 6,
wherein a width of the inner part in the direction orthogonal to the extending direction of the lead is larger than the width of the outer part in the direction orthogonal to the extending direction of the lead.
8. The semiconductor device according to claim 1,
wherein a sectional shape of the first groove is a V-shape.
9. The semiconductor device according to claim 8, further comprising:
a second groove adjacent to the first groove in the extending direction of the lead.
10. The semiconductor device according to claim 1, further comprising:
a third groove between the wire connection part and the other end inside the sealing body.
11. The semiconductor device according to claim 10,
wherein a length of the third groove is smaller than a length of the first groove in a direction orthogonal to the extending direction of the lead.
12. A semiconductor device, comprising:
a semiconductor chip that has a quadrangular first surface having a first side and a second side opposed to each other and has a first pad and a plurality of second pads on the first surface;
a first lead and a second lead that extend in a direction orthogonal to the first side and the second side of the semiconductor chip and have a main surface and a rear surface opposed to the main surface;
a first wire that is connected to the main surface of the first lead and electrically connects the first pad of the semiconductor chip and the first lead;
a plurality of second wires that are connected to the main surface of the second lead and electrically connect the plurality of second pads of the semiconductor chip and the second lead; and
a sealing body in which the semiconductor chip, the first lead, the second lead, the first wire and the second wire are covered with sealing resin,
wherein the first lead is arranged on a side of the first side of the semiconductor chip and the second lead is arranged on a side of the second side of the semiconductor chip,
the first lead has, in an extending direction of the first lead, a first end part located inside the sealing body, a second end part located outside the sealing body, and a first wire connection part which is located inside the sealing body and to which the first wire is connected,
the second lead has, in an extending direction of the second lead, a third end part located inside the sealing body, a fourth end part located outside the sealing body, and a second wire connection part which is located inside the sealing body and to which the plurality of second wires are connected,
a first groove is provided in the main surface of the first lead between the first end part and the first wire connection part, and
a flat surface is provided from the second wire connection part to the third end part on the main surface of the second lead.
13. The semiconductor device according to claim 12,
wherein the first groove extends in a direction orthogonal to the extending direction of the first lead.
14. The semiconductor device according to claim 13,
wherein the first groove is arranged between the first wire connection part and the first end part in the extending direction of the first lead.
15. The semiconductor device according to claim 12, further comprising:
a second groove between the first wire connection part and the second end part in the main surface of the first lead inside the sealing body; and
a third groove between the second wire connection part and the fourth end part in the main surface of the second lead inside the sealing body.
16. The semiconductor device according to claim 15,
wherein a length of the first groove in a direction orthogonal to the extending direction of the first lead is larger than a length of the second groove.
17. A manufacturing method of a semiconductor device, comprising:
a step of preparing a lead frame that includes: a quadrangular die pad that has a first side and a second side opposed to each other and a third side and a fourth side opposed to each other; a plurality of first leads arranged on a side of the first side of the die pad; a plurality of second leads arranged on a side of the second side of the die pad; a semiconductor chip arranged on the die pad; a plurality of first wires that electrically connect the semiconductor chip and the plurality of first leads; and a plurality of second wires that electrically connect the semiconductor chip and the plurality of second leads; and
a sealing step of placing the lead frame on a metal mold that has a cavity, a gate communicating with the cavity and a resin reservoir communicating with the cavity on an opposite side to the gate and injecting sealing resin from the gate, thereby filling the cavity and the resin reservoir with the sealing resin,
wherein the semiconductor chip, the plurality of first leads and the plurality of second leads are located in the cavity,
the gate is located on a side of the third side of the die pad and the resin reservoir is located on a side of the fourth side of the die pad, and
the sealing resin contains filler, and a thickness of the resin reservoir at a boundary part with the cavity is larger than an average particle diameter of the filler contained in the sealing resin.
18. The manufacturing method of a semiconductor device according to claim 17,
wherein the filler is made of silica.
19. The manufacturing method of a semiconductor device according to claim 17,
wherein the first lead has a wire connection part to which the first wire is connected and a groove formed between the wire connection part and the first side.
20. The manufacturing method of a semiconductor device according to claim 19,
wherein the groove extends on the first lead in parallel with the first side.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for removing a perfluorinated compound from a gas stream, the method comprising:
reacting the perfluorinated compound with steam in the presence of a catalyst comprising gallium.
2. The method of claim 1 wherein reacting the perfluorinated compound with steam is performed at a temperature above about 900\xb0 Kelvin.
3. The method of claim 1 wherein reacting the perfluorinated compound with steam is performed at a temperature in a range from about 1100\xb0 Kelvin to about 1250\xb0 Kelvin.
4. The method of claim 1 wherein the gallium comprises gallium oxide.
5. The method of claim 1 wherein the catalyst further comprises zirconium oxide.
6. The method of claim 1 further comprising passing the gas stream and a flow of water through a packed column before reacting the perfluorinated compound with steam.
7. The method of claim 1 further comprising passing the gas stream through a particulate scrubber before reacting the perfluorinated compound with steam.
8. The method of claim 1 further comprising passing the gas stream through a dry air reactor before reacting the perfluorinated compound with steam.
9. The method of claim 8 wherein the dry air reactor is at a temperature of about 1050\xb0 C. to about 1200\xb0 C.
10. The method of claim 8 wherein the dry air reactor is at a temperature of about 1150\xb0 C.
11. A method for removing a perfluorinated compound from a gas stream, the method comprising:
pre-treating the gas stream including
passing the gas stream through a first particulate scrubber, and
passing the gas stream through a first packed column; then

reacting the perfluorinated compound with steam in the presence of a catalyst comprising gallium.
12. The method of claim 11 further comprising passing the gas stream through a dry air reactor prior to passing the gas stream through the first particulate scrubber.
13. The method of claim 11 further comprising passing the gas stream through a second packed column after reacting the perfluorinated compound with steam.
14. The method of claim 11 further comprising passing the gas stream through a second particulate scrubber after reacting the perfluorinated compound with steam.
15. The method of claim 14 further comprising, after passing the gas stream through the second particulate scrubber, passing the gas stream through a second packed column.
16. A system for removing a perfluorinated compound from a gas stream, the system comprising:
a reactor vessel including a catalyst bed comprising a catalyst material including gallium disposed on an alumina substrate; and
a first packed column in fluid communication with an outlet of the reactor vessel and configured to receive a flow of water therethrough.
17. The system of claim 16 further comprising a first particulate scrubber disposed in fluid communication between the reactor vessel and the first packed column.
18. The system of claim 16 further comprising a dry air reactor in fluid communication with an inlet of the reactor vessel.
19. The system of claim 18 further comprising a second particulate scrubber in fluid communication between the dry air reactor and inlet of the reactor vessel.
20. The system of claim 19 further comprising a second packed column in fluid communication between the dry air reactor and the inlet of the reactor vessel.
21. The system of claim 20 further comprising a second particulate scrubber in fluid communication between the dry air reactor and the second packed column.
22. The system of claim 16 wherein a concentration of gallium within the catalyst material is in a range of about 20% to about 40% by weight.
23. The system of claim 16 wherein a concentration of the gallium within the catalyst material is in a range of about 27% to about 32% by weight.
24. The system of claim 16 wherein the catalyst material further includes zirconium oxide.
25. The system of claim 24 wherein a concentration of the zirconium oxide within the catalyst material is in a range of about 2% to about 10% by weight.
26. The system of claim 24 wherein a concentration of the zirconium oxide within the catalyst material is in a range of about 5% to about 7% by weight.
27. A system for removing a perfluorinated compound from a gas stream, the system comprising:
a dry air reactor;
a first packed column configured to receive a first flow of water therethrough;
a first particulate scrubber in fluid communication between the dry air reactor and the first packed column and configured to receive a second flow of water therethrough;
a reactor vessel including
an inlet in fluid communication with the first packed column,
an outlet, and
a catalyst bed comprising a catalyst material including gallium disposed on an alumina substrate;

a second packed column configured to receive a third flow of water therethrough; and
a second particulate scrubber in fluid communication between the outlet of the reactor vessel and the second packed column and configured to receive a fourth flow of water therethrough.
28. The system of claim 27 further comprising a sump, wherein the first and second particulate scrubbers and the first and second packed columns are each configured to drain into the sump.
29. The system of claim 27 wherein the sump provides the fluid communication between the first particulate scrubber and the first packed column, and also provides the fluid communication between the second particulate scrubber and the second packed column.
30. The system of claim 27 further comprising a recirculation system configured to recirculate water from the sump to the first and second particulate scrubbers and the first and second packed columns.
31. A method for removing a perfluorinated compound from a gas stream including carbon monoxide, the method comprising:
reacting the carbon monoxide with steam in the presence of a catalyst comprising gallium to produce hydrogen;
reacting the perfluorinated compound with steam and the hydrogen in the presence of the catalyst.

1461083877-f3fcec02-eea1-43f7-9d96-cacf54e12704

1. A method for the cryopreservation of oocytes or embryos, which comprises centrifugation of oocytes or embryos to polarise cytoplasmic lipid outside the oocyte or embryonic cells, subjecting the oocytes or embryos to low temperature conditions in the presence of a cryoprotectant which results in freezing of the oocytes or embryos prior to lipid depolarisation, followed by low temperature storage of the frozen lipid polarised oocytes or embryos.
2. A method according to claim 1 wherein the embryos are zona intact embryos.
3. A method according to claim 1 wherein oocytes and embryos are obtained from companion animals (for example dogs and cats), and domesticlivestock animals (for example horses, cows, sheep, goats, llamas and alpacas).
4. A method according to claim 3 wherein the oocytes and embryos are porcine oocytes and embryos.
5. A method according to claim 1 wherein the embryos are vitrified in the presence of a solution containing one or more cryoprotectant agents.
6. A method according to claim 2 wherein the cryoprotectants are selected from dimethylsulfoxide, propylene glycol, ethylene glycol, glycerol, PVP, sucrose, trehalose, Ficoll, acetamide and egg yolk.
7. A method for producing live animals from embryos which comprises thawing a cryopreserved zona intact embryo produced according to claim 1 and thereafter introducing the embryo into the uterus or fallopian tubes of a pregnancy competent female pig which at the conclusion of pregnancy term gives rise to live piglets.
8. An animal produced form a cryopreserved oocyte or embryo produced according to claim 1.
9. An animal produced according to the method of claim 7.
10. An animal according to claim 7 which is a pig.
11. A cryopreserved oocyte or embryo when produced according to claim 1.
12. A method according to claim 3 wherein embryos are vitrified by freezing in liquid nitrogen.
13. A method according to claim 10 wherein oocytes or embryos are frozen in a freezing vessel including cytologic vials or freezing straws including open pulled straws in which the oocytes or embryos are located by capillary action.
14. A method according to claim 2 wherein the embryos are in the morulae to mid-blastocyst stage.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A method for constructing a library of antibody sequences, the method comprising the steps of:
providing an amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody;
identifying the amino acid sequences in the CDRs of the lead antibody;
selecting one of the CDRs in the VH or VL region of the lead antibody;
providing an amino acid sequence that comprises at least 3 consecutive amino acid residues in the selected CDR, the selected amino acid sequence being a lead sequence;
comparing the lead sequence with a plurality of tester protein sequences; and
selecting from the plurality of tester protein sequences at least two peptide segments that have at least 15% sequence identity with the lead sequence, the selected peptide segments forming a hit library.
2. The method of claim 1, wherein the length of the lead sequence is between 5-100 aa.
3. The method of claim 1, wherein the length of the lead sequence is between 6-80 aa.
4. The method of claim 1, wherein the length of the lead sequence is between 8-50 aa.
5. The method of claim 1, wherein the step of identifying the amino sequences in the CDRs is carried out by using Kabat criteria; other criteria such as Chothia etc can be also used (quote them).
or Chothia criteria.
6. The method of claim 1, wherein the lead sequence comprises an amino acid sequence from a region within the VH or VL of the lead antibody selected from the group consisting of CDR1, CDR2, CDR3, FR1-CDR1, CDR1-FR2, FR2, CDR2, CDR2-FR3, FR3-CDR3, CDR3-FR4, FR1-CDR1-FR2, FR2-CDR2-FR3, and FR3-CDR3-FR4.
7. The method of claim 1, wherein the lead sequence comprises at least 6 consecutive amino acid residues in the selected CDR.
8. The method of claim 1, wherein the lead sequence comprises at least 7 consecutive amino acid residues in the selected CDR.
9. The method of claim 1, wherein the lead sequence comprises all of the amino acid residues in the selected CDR.
10. The method of claim 1, wherein the lead sequence further comprises at least one of the amino acid residues immediately adjacent to the selected CDR.
11. The method of claim 1, wherein the lead sequence further comprises at least one of the amino acid residues in the FRs flanking the selected CDR.
12. The method of claim 1, wherein the lead sequence further comprises one or more CDRs or FRs adjacent the C-terminus or N-terminus of the selected CDR.
13. The method of claim 1, wherein the plurality of tester protein sequences comprises antibody sequences.
14. The method of claim 1, wherein the plurality of tester protein sequences comprises human antibody sequences.
15. The method of claim 1, wherein the plurality of tester protein sequences comprises humanized antibody sequences having at least 70% human sequences in VH or VL.
16. The method of claim 1, wherein the plurality of tester protein sequences comprises human germline antibody sequences.
17. The method of claim 1, wherein the plurality of tester protein sequences is retrieved from a database consisting of genbank of the NIH, Swiss-Prot database, and the Kabat database for CDRs of antibodies.
18. The method of claim 1, wherein the step of comparing the lead sequence with the plurality of tester protein sequences is implemented by an algorithm selected from the group consisting of BLAST, PSI-BLAST, profile HMM, and COBLATH.
19. The method of claim 1, wherein the sequence identity of the selected peptide segments in the hit library with the lead sequence is at least 25%.
20. The method of claim 1, wherein the sequence identity of the selected peptide segments in the hit library with the lead sequence is at least 35%.
21. The method of claim 1, wherein the sequence identity of the selected peptide segments in the hit library with the lead sequence is at least 45%.
22. The method of claim 1, further comprising the step of:
constructing a nucleic acid library comprising DNA segments encoding the amino acid sequences of the hit library.
23. The method of claim 1, further comprising the steps of:
building an amino acid positional variant profile of the hit library;
converting amino acid positional variant profile of the hit library into a nucleic acid positional variant profile by back-translating the amino acid positional variants into their corresponding genetic codons; and
constructing a degenerate nucleic acid library of DNA segments by combinatorially combining the nucleic acid positional variants.
24. The method of claim 23, wherein the genetic codons are the ones that are preferred for expression in bacteria.
25. The method of claim 23, wherein the genetic codons are the sizechosen such that the diversity of the degenerate nucleic acid library of DNA segments within the experimentally coverable diversity (<10 6 or 7) without undue experimental effort is below 1107.
26. The method of claim 23, wherein the genetic codons are the sizechosen such that the diversity of the degenerate nucleic acid library of DNA segments within the experimentally coverable diversity (<10 6 or 7) without undue experimental effort is below 1106.
27. The method of claim 23, further comprising the steps of:
introducing the DNA segments in the degenerate nucleic acid library into cells of a host organism;
expressing the DNA segments in the host cells such that recombinant antibodies containing the amino acid sequences of the hitencoded by the degenerate nucleic acid library are produced in the cells of the host organism; and
selecting the recombinant antibody that binds to a target antigen with affinity higher than 106 M1.
28. The method of claim 27, wherein the affinity of the selected recombinant antibody is higher than 108 M1.
29. The method of claim 27, wherein the affinity of the selected recombinant antibody is higher than 109 M1.
30. The method of claim 27, wherein the host organism is selected from the group consisting of bacteria, yeast, plants, insects, and mammals.
31. The method of claim 27, wherein the recombinant antibodies are selected from the group consisting of fully assembled antibodies, Fab fragments, Fv fragments, and single chain antibodies.
32. The method of claim 27, wherein the recombinant antibodies are displayed on the surface of phage particles.
33. The method of claim 32, wherein the recombinant antibodies displayed on the surface of phage particles are double-chain heterodimers formed between VH and VL.
34. The method of claim 33, wherein heterodimerization of VH and VL chains is facilitated by a heterodimer formed between two non-antibody polypeptide chains fused to the VH and VL chains, respectively.
35. The method of claim 34, wherein the non-antibody polypeptide chains are derived from heterodimeric receptors GABAB R1 (GR1) and R2 (GR2), respectively.
36. The method of claim 32, wherein the recombinant antibodies displayed on the surface of phage particles are single-chain antibodies containing VH and VL linked by a peptide linker.
37. The method of claim 36, wherein display of the single chain antibody on the surface of phage particles is facilitated by a heterodimer formed between a fusion of the single chain antibody with GR1 and a fusion of phage pIII capsid protein with GR2.
38. The method of claim 27, wherein the target antigen is selected from the group consisting of small organic molecules, proteins, peptides, nucleic acids and polycarbohydrates.
39. A method for constructing a library of antibody sequences, the method comprising the steps of:
providing an amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody;
identifying the amino acid sequences in the CDRs and FRs of the lead antibody;
selecting one of the CDRs in the VH or VL region of the lead antibody;
providing a first amino acid sequence that comprises at least 3 consecutive amino acid residues in the selected CDR, the selected amino acid sequence being a CDR lead sequence;
comparing the CDR lead sequence with a plurality of CDR tester protein sequences;
selecting from the plurality of CDR tester protein sequences at least two peptide segments that have at least 15% sequence identity with the CDR lead sequence, the selected peptide segments forming a CDR hit library;
selecting one of the FRs in the VH or VL region of the lead antibody;
providing a second amino acid sequence that comprises at least 3 consecutive amino acid residues in the selected FR, the selected amino acid sequence being a FR lead sequence;
comparing the FR lead sequence with a plurality of FR tester protein sequences; and
selecting from the plurality of FR tester protein sequences at least two peptide segments that have at least 15% sequence identity with the FR lead sequence, the selected peptide segments forming a FR hit library; and
combining the CDR hit library and the FR hit library to form a hit library.
40. The method of claim 39, wherein the plurality of CDR tester protein sequences comprises amino acid sequences of human or non-human antibodies.
41. The method of claim 39, wherein the plurality of FR tester protein sequences comprises amino acid sequences of human antibodies.
42. The method of claim 39, wherein the plurality of FR tester protein sequences comprises humanized antibody sequences having at least 70% human sequences in VH or VL.
43. The method of claim 39, wherein the plurality of tester protein sequences comprises human germline antibody sequences.
44. The method of claim 39, wherein at least one of the plurality of CDR tester protein sequences is different from the plurality of FR tester protein sequences.
45. The method of claim 39, wherein the plurality of CDR tester protein sequences are human or non-human antibody sequences and the plurality of FR tester protein sequences are human antibody sequences, preferably human germline antibody sequences.
46. The method of claim 39, further comprising the step of:
constructing a nucleic acid library comprising DNA segments encoding the amino acid sequences of the hit library.
47. The method of claim 39, further comprising the steps of:
building an amino acid positional variant profile of the CDR hit library;
converting the amino acid positional variant profile of the CDR hit library into a first nucleic acid positional variant profile by back-translating the amino acid positional variants into their corresponding genetic codons; and
constructing a degenerate CDR nucleic acid library of DNA segments by combinatorially combining the nucleic acid positional variants.
48. A method for constructing a library antibody sequences, the method comprising the steps of:
providing an amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody;
identifying the amino acid sequences in the FRs of the lead antibody;
selecting one of the FRs in the VH or VL region of the lead antibody;
providing a first amino acid sequence that comprises at least 3 consecutive amino acid residues in the selected FR, the selected amino acid sequence being a first FR lead sequence;
comparing the first lead FR sequence with a plurality of FR tester protein sequences; and
selecting from the plurality of FR tester protein sequences at least two peptide segments that have at least 15% sequence identity with the first FR lead sequence, the selected peptide segments forming a first FR hit library.
49. The method of claim 48, further comprising the steps of:
providing a second amino acid sequence that comprises at least 3 consecutive amino acid residues in a FR that is different from the selected FR, the selected amino acid sequence being a second FR lead sequence;
comparing the second FR lead sequence with the plurality of FR tester protein sequences;
selecting from the plurality of FR tester protein sequences at least two peptide segments that have at least 15% sequence identity with the second FR lead sequence, the selected peptide segments forming a second FR hit library; and
combining the first FR hit library and the second FR hit library to form a hit library.
50. The method of claim 48, wherein the lead CDR sequence comprises at least 5 consecutive amino acid residues in the selected CDR selected from the group consisting of VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the lead antibody.
51. The method of claim 48, wherein the lead FR sequence comprises at least 5 consecutive amino acid residues in the selected FR selected from the group consisting of VH FR1, VH FR2, VH FR3, VH FR4, VL FR1, VLFR2, VL FR3 and VL FR4 of the lead antibody.
52. The method of claim 48, further comprising the step of:
constructing a nucleic acid or degenerate nucleic acid library comprising DNA segments encoding the amino acid sequences of the hit library.
53. A method for constructing a library of antibody sequences based on a lead sequence profile, the method comprising the steps of:
providing an amino acid sequence of the variable region of the heavy chain (VH) or light chain (VL) of a lead antibody;
identifying the amino acid sequences in the CDRs of the lead antibody;
selecting one of the CDRs in the VH or VL region of the lead antibody;
providing an amino acid sequence that comprises at least 3 consecutive amino acid residues in the selected CDR, the selected amino acid sequence being a lead sequence;
providing a three-dimensional structure of the lead sequence;
building a lead sequence profile based on the structure of the lead sequence;
comparing the lead sequence profile with a plurality of tester protein sequences; and
selecting from the plurality of tester protein sequences at least two peptide segments that have at least 10% sequence identity with lead sequence, the selected peptide segments forming a hit library.
54. The method of claim 53, wherein the three-dimensional structure of the lead sequence is a structure derived from X-crystallography, nuclear magnetic resonance (NMR) spectroscopy or theoretical structural modeling.
55. The method of claim 53, wherein the step of building a lead sequence profile comprises the steps of:
comparing the structure of the lead sequence with the structures of a plurality of tester protein segments;
determining the root mean square difference of the main chain conformations of the lead sequence and the tester protein segments;
selecting the tester protein segments with root mean square difference of the main chain conformations less than 5 ; and
aligning the amino acid sequences of the selected tester protein segments with the lead sequence to build the lead sequence profile.
56. The method of claim 55, wherein the root mean square difference of the main chain conformations less than 4 .
57. The method of claim 55, wherein the root mean square difference of the main chain conformations less than 2 .
58. The method of claim 53, wherein the step of building a lead sequence profile comprises the steps of:
comparing the structure of the lead sequence with the structures of a plurality of tester protein segments;
determining the Z-score of the main chain conformations of the lead sequence and the tester protein segments;
selecting the segments of the tester protein segments with the Z-score higher than 2, preferably higher than 3, more preferably higher than 4, and most preferably higher than 5; and
aligning the amino acid sequences of the selected tester protein segments with the lead sequence to build the lead sequence profile.
59. The method of claim 53, wherein the step of building a lead sequence profile is implemented by an algorithm selected from the group consisting of CE, MAPS, Monte Carlo and 3D clustering algorithms.
60. The method of claim 53, further comprising the step of:
constructing a nucleic acid library comprising DNA segments encoding the amino acid sequences of the hit library.
61. The method of claim 53, further comprising the steps of:
building an amino acid positional variant profile of the hit library;
converting amino acid positional variant profile of the hit library into a nucleic acid positional variant profile by back-translating the amino acid positional variants into their corresponding trinucleotide codons; and
constructing a degenerate nucleic acid library of DNA segments by combinatorially combining the nucleic acid positional variants.
62. A computer-implemented method for constructing a library of mutant antibodies based on a lead antibody, the method comprising the steps of:
taking as an input an amino acid sequence that comprises at least 3 consecutive amino acid residues in a CDR region of the lead antibody, the amino acid sequence being a lead sequence;
employing a computer executable logic to compare the lead sequence with a plurality of tester protein sequences;
selecting from the plurality of tester protein sequences at least two peptide segments that have at least 15% sequence identity with lead sequence; and
generating as an output the selected peptide segments which form a hit library.
63. A computer-readable medium, comprising: logic for constructing a library of mutant antibodies based on a lead antibody, the logic comprising
logic which
takes as an input an amino acid sequence that comprises at least 3 consecutive amino acid residues in a CDR of the lead antibody, the amino acid sequence being a lead sequence;
compares the lead sequence with a plurality of tester protein sequences;
selects from the plurality of tester protein sequences at least two peptide segments that have at least 15% sequence identity with lead sequence; and
generates as an output the selected peptide segments which form a hit library.